Effect of Long-Term Hemodialysis on Arterial Compliance in End-Stage Renal Failure

Nephron ◽  
1993 ◽  
Vol 65 (2) ◽  
pp. 249-253 ◽  
Author(s):  
Michael Barenbrock ◽  
Claus Spieker ◽  
Volker Laske ◽  
Peter Baumgart ◽  
Arnold P. G. Hoeks ◽  
...  
Keyword(s):  
Renal Failure ◽  
Arterial Compliance ◽  
End Stage Renal Failure ◽  
End Stage

Biopsychosocial aspects of long-term survival on end-stage renal failure therapy

1989 ◽  
Vol 19 (4) ◽  
pp. 945-954 ◽  
Author(s):  
Ralph Shulman ◽  
John D. E. Price ◽  
John Spinelli
Keyword(s):  
Renal Failure ◽  
Beck Depression Inventory ◽  
Routine Care ◽  
Renal Transplants ◽  
Term Survival ◽  
End Stage Renal Failure ◽  
End Stage ◽  
The Impact

SYNOPSISAt ten-years follow-up of 64 haemodialysis patients, 43 had died and 21 were alive, twelve with cadaver renal transplants and nine on haemodialysis. Examination of the influence of psychological, demographic, physical and biochemical factors revealed the Beck Depression Inventory and age as the two most important predictors of survival. The behaviour of the patient was directly responsible for five (11·6%) of the deaths, by suicide in three cases and dietary noncompliance in two cases. Hypothetical mechanisms linking depression with reduced survival have been reviewed. As the impact of depression on survival was maximal in the first few years of dialysis, monitoring for depression should be incorporated into routine care from the start of dialysis together with evaluative interventions that might enhance survival.

IgA nephropathy: common nephritis leading to end-stage renal failure

1994 ◽  
Vol 17 (9) ◽  
pp. 457-460 ◽  
Author(s):  
K.N. Lai ◽  
A.Y.M. Wang
Keyword(s):  
Renal Failure ◽  
Iga Nephropathy ◽  
Significant Proportion ◽  
Specific Treatment ◽  
Prognostic Indicators ◽  
Initial Report ◽  
End Stage Renal Failure ◽  
High Incidence ◽  
End Stage

IgA nephropathy (IgAN) characterized by mesangial proliferative glomerulonephritis with predominant mesangial IgA deposition is the commonest glomerulonephritis worldwide. In contrast to the initial report indicated a favorable prognosis, subsequent reports have shown a highly variable outcome leading to end-stage renal failure (ESRF) in a significant proportion of patients. Many centers report a high incidence (ranging from 10-22%) of patients with idiopathic IgAN amongst the total population of patients on maintenance dialysis. Most of these patients develop ESRF at their middle-age and hence, will pose a significant and important workload in the dialysis and transplantation programme. Because IgAN is a disease with a variable rate of progression leading to chronic renal failure amongst younger patients and with neither effective nor specific treatment, identification of the clinical and pathologic prognostic indicators for these patients is of paramount importance in planning the long-term renal replacement program.

scholarly journals Long‐term impact of renal transplantation on carotid artery properties and on ventricular hypertrophy in end‐stage renal failure patients

2002 ◽  
Vol 17 (4) ◽  
pp. 645-651 ◽  
Author(s):  
Jose Jayme G. De Lima ◽  
Marcelo Luis C. Vieira ◽  
Luis Fernando Viviani ◽  
Caio Jorge Medeiros ◽  
Luis Estevan Ianhez ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Transplantation ◽  
Carotid Artery ◽  
Ventricular Hypertrophy ◽  
End Stage Renal Failure ◽  
Long Term Impact ◽  
End Stage

Short- and long-term biological variation of cardiac troponin I in healthy individuals, and patients with end-stage renal failure requiring haemodialysis or cardiomyopathy

2020 ◽  
Vol 58 (11) ◽  
pp. 1941-1949
Author(s):  
Nick S. R. Lan ◽  
Lan T. Nguyen ◽  
Samuel D. Vasikaran ◽  
Catherine Wilson ◽  
Jacqueline Jonsson ◽  
...  
Keyword(s):  
Renal Failure ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Biological Variation ◽  
Healthy Individuals ◽  
Short Term ◽  
End Stage Renal Failure ◽  
Short And Long Term ◽  
End Stage

AbstractObjectivesHigh-sensitivity (hs) cardiac troponin (cTn) assays can quantitate small fluctuations in cTn concentration. Determining biological variation allows calculation of reference change values (RCV), to define significant changes. We assessed the short- and long-term biological variation of cardiac troponin I (cTnI) in healthy individuals and patients with renal failure requiring haemodialysis or cardiomyopathy.MethodsPlasma samples were collected hourly for 4 h and weekly for seven further weeks from 20 healthy individuals, 9 renal failure patients and 20 cardiomyopathy patients. Pre- and post-haemodialysis samples were collected weekly for 7 weeks. Samples were analysed using a hs-cTnI assay (Abbott Alinity ci-series). Within-subject biological variation (CVI), analytical variation (CVA) and between-subject biological variation (CVG) was used to calculate RCVs and index of individuality (II).ResultsFor healthy individuals, CVI, CVA, CVG, RCV and II values were 8.8, 14.0, 43.1, 45.8% and 0.38 respectively for short-term, and 41.4, 14.0, 25.8, 121.0% and 1.69 for long-term. For renal failure patients, these were 2.6, 5.8, 50.5, 17.6% and 0.30 respectively for short-term, and 19.1, 5.8, 11.2, 55.2% and 1.78 for long-term. For cardiomyopathy patients, these were 4.2, 10.0, 65.9, 30.0% and 0.16 respectively for short-term, and 17.5, 10.0, 63.1, 55.8% and 0.32 for long-term. Mean cTnI concentration was lower post-haemodialysis (15.2 vs. 17.8 ng/L, p < 0.0001), with a 16.9% mean relative change.ConclusionsThe biological variation of cTnI is similar between end-stage renal failure and cardiomyopathy patients, but proportionately greater in well-selected healthy individuals with very low baseline cTnI concentrations.

In end-stage renal failure, does infection lead to elevated plasma aluminium and neurotoxicity? Implications for monitoring

2005 ◽  
Vol 42 (2) ◽  
pp. 149-152 ◽  
Author(s):  
Sean Fenwick ◽  
Edward A Roberts ◽  
Balakrishna S Mahesh ◽  
Norman B Roberts
Keyword(s):  
Renal Failure ◽  
Aluminium Toxicity ◽  
Elevated Plasma ◽  
Long Term Effects ◽  
Tissue Storage ◽  
End Stage Renal Failure ◽  
Conscious Level ◽  
End Stage ◽  
And Storage

The well-described long-term effects of sustained exposure to aluminium in patients with end-stage renal failure (ESRF) are a result of uptake and storage of aluminium, leading to cellular toxicity. A case is presented suggesting that this aluminium may be mobilizable, and indicating the consequence of such release. A patient on haemodialysis (HD) presented acutely with infection, a raised CRP, decreased conscious level, impaired cognition and agitation. Subsequent neurological recovery over six to seven days appeared to follow the return of markedly elevated plasma aluminium concentrations to basal (i.e. from 25.2 μmol/L to 2.5 μmol/L; reference range <0.5 μmol/L), coupled with a resolution of the infection. The patient was on long-term aludrox therapy 3 g/day, and showed relative resistance to the exogenous hormone erythropoietin, resulting in a refractory anaemia and suggesting aluminium toxicity. A series of HD patients ( n=5) presenting with bacteraemia, not on aludrox, showed no appreciable rise in the plasma aluminium mean of 1.3 μmol/L (SD 0.9; range 0.6-2.0 μmol/L). We suggest that infection can result in release of tissue aluminium, leading to acutely elevated plasma aluminium concentrations and signs of neurotoxicity. The amount of tissue storage and resultant aluminium release seemed to be related to the use of aluminium hydroxide as a phosphate binder.

scholarly journals Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis.

Heart ◽  
1992 ◽  
Vol 67 (3) ◽  
pp. 236-239 ◽  
Author(s):  
E Straumann ◽  
B Meyer ◽  
M Misteli ◽  
A Blumberg ◽  
H R Jenzer
Keyword(s):  
Renal Failure ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Valve Disease ◽  
End Stage Renal Failure ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document